The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis
Roots
Analysis has announced the addition of “Porphyria Targeting Therapies Market” report to its list of offerings.
Porphyria is a rare disorder
that is characterized by excessive accumulation of porphyrin, a compound that
aids in the formation of heme (an essential part of hemoglobin that helps
carry oxygen in blood). Any anomaly caused by genetic or acquired
abnormalities in heme biosynthesis (produced majorly in bone marrow and liver)
can result in toxicity. It is worth highlighting that, till date, more than 1,000
mutations that can cause porphyria have been identified. However, prevalence of porphyria
still remains unknown. Several treatment options such as gene therapy,
proteasome inhibition and pharmacologic chaperones are currently being
investigated among various other targeted treatment options.
To order this 130+ slides
report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.
Key Market Insights
15+ therapies have been / are being developed for the different
type of porphyria
More than 70% of the
aforementioned candidates are currently under clinical evaluation. Further, three
therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved
for the treatment of different types of porphyria.
Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs
have been / are being designed for administration via the intravenous route.
Furthermore, majority of the drugs (37%) have been / are being targeting acute
intermittent porphyria.
Over 30% of the therapies have been / are being developed
for erythropoietic protoporphyria
More than 65% the abovementioned
therapies are currently being evaluated
in clinical phases. Further, around 60% of the aforementioned therapy
candidates are being developed as small molecules.
To request a sample copy / brochure of this report, please
visit this https://www.rootsanalysis.com/reports/porphyria-pipline-review/request-sample.html
Key
Questions Answered
§ What are the prevalent R&D trends related to Porphyria?
§ What are the key challenges faced by stakeholders engaged
in this domain?
§ What are the principal therapies developed by the companies
in this domain?
§ Who are the leading industry and non-industry players in this
market?
§ What are the key geographies where research on porphyria is
actively being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts in this field?
§ What kind of partnership models are commonly adopted by industry
stakeholders?
§ What are the factors that are likely to influence the
evolution of this upcoming market?
§ How is the current and future market opportunity likely to
be distributed across key market segments?
For additional
details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Progressive
Supranuclear Palsy: Pipeline Review, Developer Landscape and
Competitive Insights, 2021-2030
2. Soft
Tissue Sarcoma: Pipeline Review, Developer Landscape and
Competitive Insights, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest
growing market research companies, sharing fresh and independent perspectives
in the bio-pharmaceutical industry. The in-depth research, analysis and
insights are driven by an experienced leadership team which has gained many
years of significant experience in this sector. If you’d like help with your
growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis
Private Limited
Ben Johnson
+1 (415) 800 3415
Comments
Post a Comment